CEO SUMMARY: Proteomics-based technology is developing rapidly. The strategic collaboration announced last month between Ciphergen Biosystems and Quest Diagnostics Incorporated is potentially worth $25 million. It is an expensive bet that next-generation proteomics tests soon to enter the clinical marketplace will provide high clinical utility and give physicians new diagnostic tools. NEW PROTEOMIC-BASED TECHNOLOGIES ARE […]
Proteomic Tests Poised For Clinical Market
Potential for earlier detection, higher sensitivity and specificity
- By Robert Michel
- > From the Volume XII No. 12 - August 22, 2005 Issue
- Tags: aco, cap, clinical diagnostics market, clinical lab, clinical laboratories, Clinical Laboratory, clinical laboratory industry, clinical labs, clinical trials, diagnostic testing, Diagnostic tests, diagnostics market, genomics, hie, informatics, lab executive, lab manager, lab managers, lab test, lab tests, laboratories, laboratory director, laboratory industry, pathologists, personalized medicine, pharmacogenomics, the clinical laboratory
